The Medicines Co., based in New Jersey, said in a release it hosted a webcast March 17 featuring results from its ORION-1 Phase II study of inclisiran, the company’s PCSK9 synthesis inhibitor for the treatment of hypercholesterolemia.
Ferring Pharmaceuticals said it reached an agreement with Apricus Biosciences Inc. to acquire the rights and assets outside of the United States market for Apricus' Vitaros, a topical cream for erectile dysfunction.
The Food and Drug Administration (FDA) has sent AstraZeneca a complete response letter (CRL) from the regulatory board in response to the development of sodium zirconium cyclosilicate, a drug designed to treat hyperkalaemia.
Horizon Pharma plc, a biopharmaceutical company, has launched UCD in Common, an effort to educate people about urea cycle disorder, a rare genetic disease characterized by toxic levels of ammonia in the blood.
Global biopharmaceutical company AbbVie has received priority review from the Japanese Ministry of Health, Labour and Welfare for Glecaprevir/Pibrentasvir, its drug for the treatment of chronic hepatitis C.
Aeolus Pharmaceuticals Inc. recently reported that its AEOL 20415 protected the lungs in a mouse model of cystic fibrosis, increasing further speculation that the drug could be used as both a treatment for cystic fibrosis, as well as antibiotic-resistant bacteria.
The American Heart Association (AHA) has released its Precision Medicine Platform, a cloud-based resource with data geared to help doctors, computational biologists, researchers and computer engineers battle cardiovascular diseases and stroke.
Alere Inc. has announced that its respiratory syncytial virus test has been granted a Clinical Laboratory Improvement Amendments waiver by the Food and Drug Administration, paving the way for the test to be available to doctors, walk-in clinics and emergency rooms.